Prognostic Significance of Sarcomatous Change in Patients with Hepatocellular Carcinoma After Surgical Resection.
BACKGROUND
Hepatocellular carcinoma (HCC) with sarcomatous change (SC) is a rare malignancy associated with high aggressiveness and poor prognosis; however, its prognostic significance remains unclear.


METHODS
From January 1994 to April 2012, surgically resected HCCs with SC (n = 52) at West China Hospital were retrospectively reviewed. HCC with SC was defined as the concomitant presence of the sarcomatous component occupying at least 10 % (but not predominantly) of the HCC-bearing tissue. To validate its prognostic significance, we compared the clinicopathological features and survival rates of these patients with a cohort of 214 randomly selected ordinary HCC patients during the same period.


RESULTS
The clinicopathological characteristics of HCC with SC were similar to those of ordinary HCC, with the exception of capsule formation, adjacent organ invasion, lymph node metastasis, and TNM staging. A total of 45 (86.5 %) HCC patients with SC experienced a recurrence, with a median time to recurrence of 6.0 months. Overall survival (OS) rates in the sarcomatous HCC group at 1, 2, and 3 years were 55.8, 25, and 17.3 %, respectively, which were significantly lower than those in the ordinary HCC group (p < 0.001). On multivariable analysis, macrovascular invasion, satellite nodules, and R1/R2 resection were identified as independent risk factors for shorter disease-free survival and OS.


CONCLUSIONS
The presence of SC in HCC was uncommon, and was associated with much poorer prognosis than ordinary HCC. Radical resection with negative margin is essential for improving the prognosis. Future prospective studies are warranted to determine if recurrent patients can benefit from postoperative adjuvant therapies.
Department of Bile Duct Surgery, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Jiong
J
Lu
Department of Bile Duct Surgery, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Xian-Ze
XZ
Xiong
Department of Bile Duct Surgery, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Fu-Yu
FY
Li
Department of Bile Duct Surgery, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Hui
H
Ye
Department of Bile Duct Surgery, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Yi-Xin
YX
Lin
Department of Bile Duct Surgery, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Rong-Xing
RX
Zhou
Department of Bile Duct Surgery, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Yu-Long
YL
Cai
Department of Bile Duct Surgery, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Yan-Wen
YW
Jin
Department of Bile Duct Surgery, West China Hospital, Sichuan University, Chengdu, Sichuan, China. nanshengcheng@163.com.
Nan-Sheng
NS
Cheng
D000328:Adult; D000368:Aged; D006528:Carcinoma, Hepatocellular / Q000556:secondary / Q000601:surgery*; D005260:Female; D005500:Follow-Up Studies; D006498:Hepatectomy / Q000009:adverse effects*; D006801:Humans; D008113:Liver Neoplasms / Q000473:pathology / Q000601:surgery*; D008207:Lymphatic Metastasis; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D011183:Postoperative Complications; D011379:Prognosis; D012189:Retrospective Studies; D012509:Sarcoma / Q000473:pathology*; D015996:Survival Rate; D055815:Young Adult